ALERTS, HOT STOCKS & CHARTS

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Global Stocks See Slight Uptick Amid Market Volatility Tuesday saw global stocks climb, yet trading was erratic. Following Monday's forceful selloff, investors remained wary. Officials of central banks aimed at reassuring the markets. Some respite came from Tokyo overnight's 10% rebound in Nikkei. Investor mood was still wary, though. U.S. stock futures displayed mixed...

The Femtech market stood at an impressive USD 33.92 billion back in 2023, setting the stage for its remarkable leap to a projected value of USD 113.53 billion by 2031. That’s a compound annual growth rate (CAGR) of about 16.3%. So, what's fueling this explosion? For starters, it's all about the rising awareness surrounding women's health issues—a topic that finally...

Class Action Lawsuit Against Vestis Corporation Pomerantz LLP is drawing attention to a class action lawsuit filed against Vestis Corporation (NYSE: VSTS) concerning allegations of securities fraud. Investors who have incurred losses due to their investment in Vestis are encouraged to take action. Deadline for Investors Investors have until August 8, 2025, to request the...

Associated Banc-Corp Announces Stock Offering Associated Banc-Corp (NYSE: ASB) has recently made headlines with its announcement regarding a public offering of its common stock. The company is set to offer 12 million shares, each with a par value of $0.01, at a price of $25.00 per share. This means the total gross proceeds from this offering are expected to reach an...

Olaplex Holdings Inc. to Engage at Canaccord Genuity Growth Conference Olaplex Holdings, Inc. (NASDAQ: OLPX) has recently confirmed its engagement in the Canaccord Genuity 45th Annual Growth Conference. This prestigious event is set to take place soon, where the company will have a platform to showcase its commitment to innovation in the beauty and hair care industry....